As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Relugolix–estradiol–norethisterone acetate for treating pain from endometriosis.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.